Patent SG-11201809790X-A (SG)
Title: Immune system modulation for prophylaxis and treatment of diseases and disorders
Inventor: WILLEFORD KENNETH O
IPC: C07K7/00
Filed: 2017-04-04
Abstract: INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property ' Organization 111111110111101110101011111010111110111010111111001111110011111111101111011111 International Bureau ... .l jd ..... ..../ (10) International Publication Number (43) International Publication Date WO 2017/176757 Al 12 October 2017(12.10.2017) WIPO I PCT (51) International Patent Classification: A61K 38/00 (2006.01) A61P 37/00 A61K 38/48 (2006.01) CO7K 7/00 (21) International Application Number: (22) International Filing Date: (25) Filing Language: (26) Publication Language: (30) Priority Data: 62/318,016 4 April 2016 (04.04.2016) 62/453,586 2 February 2017 (02.02.2017) 62/455,166 6 February 2017 (06.02.2017) (71) Applicant: MARPE HOLDINGS, NW 24th Way, Boca Raton, Florida 33431 (US). (72) Inventors: WILLEFORD, Kenneth Drive, Starkville, Mississippi 39759 Douglas A.; 234 West Bandera Road; #122, Boerne, Texas 4 April (81) Designated States (unless otherwise indicated, for every (2006.01) kind of national protection available): AE, AG, AL, AM, (2006.01) AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, PCT/US2017/025947 HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, 2017 (04.04.2017) MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, English RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, English TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. US (84) Designated States (unless otherwise indicated, for every US kind of regional protection available): ARIPO (BW, GH, US GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, LLC [US/US]; 2907 TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, L 0.; 105 Daffodil V, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, (US). MCCLAIN, GW, KM, ML, MR, NE, SN, TD, TG). Published: al.; Remenick PLLC, - with international search report (Art. 21(3)) 175, Washington, - with sequence listing part of description (Rule 5.2(a)) 78006 (US). (74) Agents: REMENICK, James et 1025 Thomas Jefferson St., NW, Suite District 20007 (US). of Columbia FOR PROPHYLAXIS AND TREATMENT OF DISEASES AND DISORDERS CYTOKINE LEVELS AT VARIOUS TIMES AFTERADMINISTRATION OF NPIS40 (pON) = Title: IMMUNE SYSTEM MODULATION (54) TIME L-2 IL-4 IL-6 IL-8 IL-10 VEGF Inf-o INF-0 11-1A IL-1B MCP-1 EGF 0 7 1.813 63 2.54 188.76 1.07 3.07 0 1.94 262.62 5.56 0 0 222 205.78 2.41 268.99 0 7.03 037 1.79 351.48 163.84 0 1.69 1.67 174 2.1 19233 C 2.34 112 1.79 310.95 1558 0 1.55 2.55 113 2.54 203.17 0 2.4 0.92 1.79 369.8 4.41 0 0 1.5 15.43 0 50.55 0 1.68 335 C 337.45 J.32 0 0 3.11 347.47 0 97.96 0 3.97 035 0 459.24 251.14 0 1.55 145 11.81 0 56.31 0 1.95 0.98 1.72 383.63 24.02 0 0 ',.56 12.23 149 48.79 0 1.73 0.86 0 400.13 2.81 0 o 8.93 9.88 0 80.59 0 118 0 0 273.27 2.63 0 0 8.08 118.63 1.31 107.21 0 5.66 0.39 C 320.85 300.18 0 1.62 2.59 4.74 1.31 58.02 0 2.96 1.83 0 234.04 31.68 0 0 2.93 10.91 4.73 81.12 0 3.35 0.71 0 354.49 7.2 0 0 133 14.68 0 75.74 0 2.34 0 0 203.29 0 0 0 2.06 206.08 0 98.48 0 191 0 0 210.62 14022 7 7 099 11 03 0 78.44 0 2.6B 0 0 182.21 10.34 0 0 0.95 9.27 0 74.66 0 2.96 1.91 7 17241 10.22 11.12 1.62 0.85 24.62 1.92 20637 2.12 2.62 0.71 4.24 437.47 20.42 8.24 1.76 1.18 17.06 .67 144.98 1.65 2.12 0.78 4.1 257.94 25.66 10.18 1.89 145 21.42 1.98 150.31 165 2.96 0.94 4.45 360.26 7.27 0 0 11.92 27.9 43.1 257.34 1.18 6.57 0 1.72 826.32 45.86 0 t55 24.15 59.33 50.62 307.11 1.23 6.63 0.57 2.78 1161.12 56.59 4 31 biological response modifiers (BRM) which may contain one or more compounds, and to system with BRMs of the invention including augmenting a specific immune response an adjuvant or vaccine when coupled with a pathogenic antigen, and for boosting an im - directed to the reduction of an unrestrained or improper inflammatory response and/or autoimmune diseases and disorders, and associated symptoms. Further, the invention comprising isolated serum from a mammal, and subjecting that serum to tangen- cut-off dialysis to obtain one or more purified BRM compounds suitable for admin- SUBJECT (h) 101 0 3 24 48 102 0 3 24 48 103 0 3 24 48 104 0 3 24 48 105 0 11 3 24 106 0 Ir----- 3 IN FIG. IN ,tD N (57) : The invention is directed to 1-1 ---- methods for enhancement of an immune N either prophylactically or for treatment, as c:::: : , mune system generally. The invention is also ei an immune response such as to treat or prevent O is directed to the manufacture of BRM compounds tial flow chromatography and molecular weight istration to a patient in need.